Novel Molecular Multilevel Targeted Antitumor Agents.

Area of Science:

• Biotechnology
• Molecular Biology
• Cancer Research

Background:

• Glioblastoma (GBM) is an aggressive brain tumor with limited treatment options.
• Targeting specific cellular organelles for drug delivery can enhance anti-cancer efficacy and reduce side effects.
• Current therapies often lack specificity, leading to systemic toxicity.

Purpose of the Study:

• To engineer multifunctional fusion proteins for targeted delivery of anti-cancer agents to glioblastoma cells.
• To investigate the intracellular localization and efficacy of novel fusion proteins targeting lysosomes and mitochondria.
• To evaluate the cytotoxic potential of these engineered proteins, alone and conjugated with doxorubicin, against GBM cells.

Main Methods:

• Construction of fusion proteins incorporating IL-13.E13K targeting ligand, Pseudomonas exotoxin A domain (D2), and organelle localization signals (NLS, LLS, KK2).
• Site-specific conjugation of fusion proteins with a modified doxorubicin (WP936) via a cysteine residue.
• Assessment of protein internalization, intracellular trafficking, and cytotoxicity in GBM cell lines with varying IL-13RA2 receptor expression.

Main Results:

• Engineered proteins IL-13.E13K-D2-LLS and IL-13-D2-KK2 were successfully targeted to lysosomes and mitochondria, respectively.
• Fusion proteins conjugated with WP936 demonstrated significant cytotoxicity against IL-13RA2-overexpressing GBM cells.
• IL-13.E13K-D2-NLS-cys[WP936] exhibited superior anti-tumor potency compared to free WP936 and other tested agents.

Conclusions:

• Receptor-directed, intracellular organelle-targeted fusion proteins represent a novel strategy for glioblastoma treatment.
• These engineered proteins offer enhanced specificity and potency, with potential for safer and more effective cancer therapies.
• Targeting specific intracellular compartments allows for precise drug action, minimizing off-target effects.